Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort

JHVEPhoto Pfizer Inc. (NYSE:PFE) stock has continued to reel from the exhaustion of COVID dollars. Specifically, the 2023 downturn has been primarily dragged by a faster-than-expected normalization of Comirnaty vaccine and Paxlovid COVID treatment uptakes. In addition to the $5.6 billion write-off on Paxlovid/Comirnaty inventory in Q3, management has also provided a weaker-than-expected guidance for said products in 2024. Specifically, management guides $8 billion in Comirnaty/Paxlovid revenue for 2024, und ...